[3]Theresa A McDonagh, Marco Metra, Marianna Adamo, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, ehab368, 27 August 2021.
[4]Vaduganathan, Muthiah, et al. "Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials." The Lancet (2020).
[5]John J VMcMurray,et al.Atrialto evaluatethe effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced leftventricular ejection fraction(DAPA-HF)[J].EurJ Heart Fail.2019 May;21(5):665-675.doi: 10.1002/ejhf.1432.Epub 2019 Mar 21.